A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic ScreeningMichael L. Beshiri, Kathleen Kelly, Caitlin M. Tice et al.|Clinical Cancer Research|2018Cited by 236
Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancerHong Pan, Kathleen Kelly, Keith H. Jansson et al.|Oncotarget|2017Cited by 45
High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancerKeith H. Jansson, Kathleen Kelly, Ross Lake et al.|Scientific Reports|2018Cited by 33
Castrate-resistant prostate cancer response to taxane is determined by an HNF1-dependent apoptosis resistance circuitIlya S. Senatorov, Kathleen Kelly, Joel M. Bowman et al.|Cell Reports Medicine|2024Cited by 5
Supplementary Tables from A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic ScreeningMichael L. Beshiri, Kathleen Kelly, Caitlin M. Tice et al.|Unknown|2023Cited by 0